Poseida Therapeutics Receives US FDA Orphan Drug Designation for P-BCMA-101 for the Treatment of Multiple Myeloma
13 mai 2019 08h00 HE
|
Poseida Therapeutics, Inc.
SAN DIEGO, May 13, 2019 (GLOBE NEWSWIRE) -- Poseida Therapeutics Inc., a clinical-stage biopharmaceutical company leveraging proprietary non-viral gene engineering technologies to create life-saving...
Poseida Therapeutics Raises $142 Million in Series C Financing
22 avr. 2019 07h00 HE
|
Poseida Therapeutics, Inc.
SAN DIEGO, April 22, 2019 (GLOBE NEWSWIRE) -- Poseida Therapeutics Inc., a clinical-stage biopharmaceutical company leveraging proprietary non-viral gene engineering technologies to create...
Poseida Therapeutics Announces Notice of Allowance for New Patents and Registration of New Trademarks
13 févr. 2019 08h00 HE
|
Poseida Therapeutics, Inc.
SAN DIEGO, Feb. 13, 2019 (GLOBE NEWSWIRE) -- Poseida Therapeutics Inc., a clinical-stage biopharmaceutical company leveraging proprietary non-viral gene engineering technologies to create...
Poseida Therapeutics Appoints Two Independent Directors, Adding Leaders for Compensation and Governance Functions
04 janv. 2019 16h53 HE
|
Poseida Therapeutics, Inc.
SAN DIEGO, Jan. 04, 2019 (GLOBE NEWSWIRE) -- Poseida Therapeutics Inc., a clinical-stage biopharmaceutical company leveraging proprietary non-viral gene engineering technologies to create...
Poseida Therapeutics Provides Update on Phase 1 Study of P-BCMA-101 CAR-T Product Candidate at the 2018 American Society of Hematology Annual Meeting
03 déc. 2018 21h15 HE
|
Poseida Therapeutics, Inc.
SAN DIEGO, Dec. 03, 2018 (GLOBE NEWSWIRE) -- Poseida Therapeutics Inc., a clinical-stage biopharmaceutical company leveraging proprietary non-viral gene engineering technologies to create...
Poseida Therapeutics to Provide Update on Phase 1 Study of P-BCMA-101 at the 2018 American Society of Hematology Annual Meeting
29 nov. 2018 08h00 HE
|
Poseida Therapeutics, Inc.
SAN DIEGO, Nov. 29, 2018 (GLOBE NEWSWIRE) -- Poseida Therapeutics Inc., a clinical-stage biopharmaceutical company focused on leveraging proprietary next-generation, non-viral gene engineering...
Poseida Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for P-BCMA-101
05 nov. 2018 08h00 HE
|
Poseida Therapeutics, Inc.
SAN DIEGO, Nov. 05, 2018 (GLOBE NEWSWIRE) -- Poseida Therapeutics Inc., a clinical-stage biopharmaceutical company focused on leveraging proprietary next-generation, non-viral gene engineering...
Poseida Therapeutics Appoints Marcy Graham as Vice President, Corporate Affairs
09 oct. 2018 08h00 HE
|
Poseida Therapeutics, Inc.
SAN DIEGO, Oct. 09, 2018 (GLOBE NEWSWIRE) -- Poseida Therapeutics Inc., a San Diego-based company translating best-in-class gene engineering technologies into lifesaving cell therapies, today...
Poseida Provides Update on Phase 1 Study of P-BCMA-101 CAR-T Stem Cell Memory Product in Patients with Relapsed/Refractory Multiple Myeloma
05 sept. 2018 09h15 HE
|
Poseida Therapeutics, Inc.
Efficacy and safety continue to be a major advantage, with a very high response rate, no dose limiting toxicities and only a single incidence of suspected cytokine release syndrome P-BCMA-101...
Poseida Therapeutics’ Clinical Update of BCMA-specific CAR-T Program Selected as a Late Breaking Presentation at the 4th Annual CAR-TCR Summit 2018
29 août 2018 05h00 HE
|
Poseida Therapeutics, Inc.
SAN DIEGO, Aug. 29, 2018 (GLOBE NEWSWIRE) -- Poseida Therapeutics Inc. (“Poseida”), a San Diego-based company translating best-in-class gene engineering technologies into lifesaving cell therapies,...